64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression. (21st February 2023)

• Record Type: Journal Article
• Authors: Lee, Inki; Lim, Ilhan; Lee, Kyo Chul; Kang, Hye Jin; Lim, Sang Moo
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 2(2023)
• Page Start: e82
• Page End: e83
• Publication Date: 2023-02-21
• Subjects: 64Cu-DOTA-rituximab -- B-cell lymphoma -- CD20 antigen -- positron emission tomography; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004378
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: 64 Cu-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with 18 F-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no discernible 64 Cu-DOTA-rituximab uptake in the tumor other than lymphoma. 64 Cu-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma because of imaging the CD20 expression.